However, the likelihood of response is improved by midostaurin and relapse rates decrease when either agent is combined with frontline 7 + 3 induction therapy in patients with newly diagnosed FLT3-mutated AML [16, 17]. The gene discussed is FLT3; the disease is acute myeloid leukemia.